Brief: Transgene: First Patient Enrolled In Phase II Clinical Trial Of Cancer Vaccine TG4050
03/06/2024 06:34
June 3 (Reuters) - Transgene SA TRNG.PA :
* FIRST PATIENT ENROLLED IN PHASE II PART OF RANDOMIZED
PHASE I/II
TRIAL EVALUATING LEAD CANCER VACCINE TG4050 IN HEAD AND NECK
CANCER
* LAST PATIENT ENROLLMENT FOR PHASE II PART EXPECTED IN Q4
2025
* TG4050 ADVANCING TO PHASE II PART BASED ON PHASE I DATA
SHOWING
IMMUNOGENICITY AND FIRST SIGNS OF CLINICAL BENEFIT
Source text for Workspace: ID:nGNE1lG1K0
Further company coverage: TRNG.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs